Catalog No.
KDA29102
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD262 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Conatumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Conatumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Conatumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Conatumumab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
78.13 - 5,000 ng/mL
Sensitivity
91.95 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
2786.1 |
664.0 |
174.6 |
2871.2 |
689.7 |
144.4 |
|
Standard deviation |
316.0 |
54.2 |
28.8 |
334.6 |
39.5 |
19.0 |
|
CV (%) |
11.3 |
8.2 |
16.5 |
11.7 |
5.7 |
13.2 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
AMG 655, TRAIL-R2mAb, XG1-048 v w, CAS: 896731-82-1
Background
Conatumumab (previously called AMG-655) is a fully human Immunoglobulin G1 (IgG1) type monoclonal binding to tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) which could induce apoptosis in many types of human cancer cells. This drug was developed by Amgen Inc and Japanese licensee Takeda Bio Development Center Ltd with potential antineoplastic activity. This drug has been investigated in trials studying the treatment of sarcoma, lymphoma, oncology, colon cancer, and rectal cancer. Conatumumab can elicit the apoptosis in cell lines derived from colon and pancreatic cancers, as well as in mice bearing xenograft tumors in some in vitro and in vivo assays. Clinical trials in phase I has assessed the safety of conatumumab as a monotherapy as well as in combination with other antibody therapies or standard chemotherapeutic regimes. And the anti-conatumumab antibody responses have not been observed in previous trials. In addition, conatumumab has been found to enhance the antitumor activity of agents like irinotecan and gemcitabine in some preclinical researches. A trail about conatumumab combined with AMG 479 has shown that it is well-tolerated and no drug-drug interactions and the phase II development of this combination is ongoing.
For research use only. Not for human or drug use.
